Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses

International Journal of Cancer

Volumn 118, Issue 6, 2006, Pages 1508-1514

  Ferguson, Morag ^a   Heath, Alan ^a   Johnes, Suzanne ^a   Pagliusi, Sonia ^b   Dillner, Joakim ^c  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Antibody; Human papilloma virus; Standardization; VLPs

Indexed keywords

CAPSID PROTEIN; VIRUS ANTIBODY; VIRUS DNA; VIRUS PROTEIN; WART VIRUS VACCINE;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME IMMUNOASSAY; FEMALE; FEMALE GENITAL TRACT INFECTION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEROCONVERSION; SEROEPIDEMIOLOGY; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WART VIRUS;

ANTIBODIES, VIRAL; CAPSID PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOASSAY; INTERNATIONAL COOPERATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

EID: 33644532837     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21515     Document Type: Article

References (21)

1. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
2. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
3. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
4. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
5. World Health Organization. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting. Geneva, 16-18 Feb 1999. Available from the WHO website at http://www.who.int/vaccine_research/documents/en/hpv1.pdf
6. World Health Organization. Assessment and harmonization of laboratory diagnostic procedures related to human papillomavirus vaccine research and development. Report of a technical meeting, Heidelberg, 6-7 March 2001. Available from the WHO website at http://www.who.int/vaccine_research/documents/ en/hpv2.pdf
7. World Health Organization. Development of international HPV reference reagents. WHO informal workshop, Florianópolis, Brazil, 2-4 Sept 2001, Available from the WHO website at http://www.who.int/vaccines-documents/ DocsPDF02/www699.pdf
8. Andersson-Ellström A, Dillner J, Hagmar B, Schiller J, Sapp M, Forssman L, Milsom I. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996;23:234-8.
9. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angström T, Dillner J. Smoking, diet, pregnancy, and oral contraceptive use as risk factors for cervical intraepithelial neoplasia, in relation to human papillomavirus infection. Br J of Cancer 2000;82:1332-8.
10. Silins I, Wang X, Tadesse A, Jansen KU, Schiller JT, Avall-Lundqvist E, Frankendahl B, Dillner J. A population-based study of cervical carcinoma and HPV infection in Latvia. Gynecol Oncol 2004;93:484-92.
11. Heino P, Eklund C, Fredriksson-Shanazarian V, Goldman S, Schiller JT, Dillner J. Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst 1995;87:437-40.
12. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003;95:1128-37.
13. Touze A, de Sanjose S, Coursaget P, Almirall MR, Palacio V, Meijer CJ, Kornegay J, Bosch FX. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 2001;39:4344-8.
14. Studentsov YY, Schiffman M, Strickler HD, Ho GYF, Pang Y-YS, Schiller J, Herrero R, Burk RD. Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol 2002;40:1755-60.
15. Rosenblatt KA, Carter JJ, Iwasak LMI, Galloway DA, Stanford JL. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:763-8.
16. Liu Y, Liu X, Frazer IH. Immunogenicity study of HPV 6b virus-like particles. Zhonghua Yi Xue Za Zhi 2002;82:587-9.
17. Palker TJ, Monteiro JM, Martin MM, Kakareka C, Smith JF, Cook JC, Joyce JG, Jansen KU. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 2001;19:3733-43.
18. Sehr P, Muller M, Hopfl R, Widschwendter A, Pawlita M. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002;106:61-70.
19. Finney DJ. Statistical methods in biological assay, 3rd ed. London: Charles Griffin, 1978.
20. Ferguson M, Sands D, Lelie N. Collaborative study on the proposed replacement international standard for hepatitis A immunoglobulin. Biologicals 2001;28:233-40.
21. Ferguson M, Heath A. Report of a collaborative study to calibrate the second international standard for parvovirus B19 antibody. Biologicals 2004;32:207-12.